WHO is convening a Guideline Development Group (GDG) for the development of Updated recommendations on antiretroviral therapy, management of vertical HIV transmission, and TB prevention in people living with HIV.
GDG members will contribute to the review of systematic reviews, evidence summaries, technical updates, and will propose recommendations. They will participate in the GDG meeting, which will be held in a series of virtual sessions on 18, 19, 20, 25, 26 February 2025, and on 4, 5, 25, 26, 27 March 2025.
The general objective of this meeting is to develop recommendations on use of newer antiretroviral drugs or regimens for HIV treatment and update existing recommendations on preferred drugs or regimens to be used in second- and third line ART, prophylactic regimens and breastfeeding practices for management of infants at risk of vertical transmission, and preferred tuberculosis preventive therapy (TPT) in people living with HIV who start or are receiving antiretrovirals for HIV treatment.
The specific objectives include:
- to review the evidence supporting the formulation of new and updated recommendations;
- to review associated information to support the evidence-to-decision process: benefits versus harms, values and preferences, feasibility, resource use, equity and cost; and
- to formulate recommendations for the PICO.
Guideline Development Group composition
In accordance with WHO guidelines for developing recommendations , the GDG is composed of members from all WHO regions, serving in their individual capacities rather than as representatives of affiliated organizations. GDG members were selected by WHO technical staff based on their technical expertise, their role as end-users (e.g., programme managers and healthcare providers), and their representation of affected communities. Members do not receive financial compensation for their contributions to this process.
